Epitope Diagnostics, Inc.
Epitope Diagnostics Inc. (EDI) strives to develop, manufacture, and market the highest quality and most innovative in-vitro diagnostics (IVD) products to the global research, pharmaceutical, and healthcare community. We seek to become a major contributor in resolving the unmet medical needs of the world.
Press Releases
-
The QSE180 is a fully automated, random-access stool sample auto sampler and auto extractor, our already standardized pre-packed collection kits can be used in this automated sampler/ autoextractor. This game-changing technology automates everything for sample collection, which significantly improving efficiency, accuracy, and reliability in the laboratory. By reducing human error and operational costs, it ensures more dependable results for clinicians and better outcomes for patients.
-
Epitope Diagnostics, Inc. has officially launched its fully automated chemiluminescent immunoassay analyzers (ECL25 and ECL100) together with panel kits of routine and niche chemiluminescence immunoassay tests covering different clinical areas. Please check our advert on the Clinical Chemistry Journal Volume 69 Issue 2 from February 2023.
-
Stool sample testing plays a crucial role in providing valuable information for clinical diagnosis and monitoring various gastrointestinal diseases. With a dedicated focus on stool sample tests for over 15 years, Epitope Diagnostics has successfully developed a comprehensive panel of test manuals and user-friendly devices specifically designed for easy fecal sample collection and extraction. Our commitment to this field enables us to offer reliable and efficient solutions for gastrointestinal testing.
-
Epitope Diagnostics is proud to introduce its fully automated chemiluminescence immunoassay (CLIA) kit, exclusively designed for the quantitative measurement of serum chromogranin A (CgA, Catalog # CL0820). This marks another significant milestone in our ongoing commitment to innovation and development, following the successful introduction and manufacturing of chromogranin A ELISA kits ten years ago. The new CgA CLIA offers numerous advantages for professional laboratory operations, including a short incubation time period and the ability to obtain test results within minutes using random access ECL100 or ECL25 analyzers.